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Abstract: Dengue is a neglected disease responsible for 22,000 deaths each year in areas 
where it is endemic. To date, there is no clinically approved dengue vaccine or antiviral for 
human beings, even though there have been great efforts to accomplish these goals. Several 
approaches have been used in the search for dengue antivirals such as screening of 
compounds against dengue virus enzymes and structure-based computational discovery. 
During the last decades, researchers have turned their attention to nature, trying to identify 
compounds that can be used as dengue antivirals. Nature represents a vast reservoir of 
substances that can be explored with the aim of discovering new leads that can be either 
used directly as pharmaceuticals or can serve as lead structures that can be optimized 
towards the development of new antiviral agents against dengue. In this review we describe 
an assortment of natural products that have been reported as possessing dengue antiviral 
activity. The natural products are organized into classes of substances. When appropriate, 
structure-activity relationships are outlined. The biological assays used to assess antiviral 
activity are briefly described. 
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1. Introduction 
Dengue fever (DF) and dengue hemorrhagic fever (DHF) are acute febrile diseases transmitted by 
mosquitoes. Nowadays, they are the most rapidly spreading mosquito-borne diseases in the world. 
About 2.5 billion people, two-fifths of the world’s population, are now at risk of infection and   
50 million cases of DF are reported worldwide every year [1]. In recent decades, these diseases have 
spread to over more than 100 countries [2]. The World Health Organization (WHO) estimates that the 
annual global incidence of dengue is close to 390 million, a number nearly three times higher than the 
number of cases estimated by the same organization for 2009 [3].  
Increased urbanization along with substandard housing, unreliable water supply, and poor sanitation 
provide a suitable environment for vector proliferation in close proximity to human hosts. Dengue 
proliferation became even more problematic in the Americas due to the collapse of vector eradication 
programs in the 1970s [4]. 
The dengue virus particle is about 50 nm in diameter. The 10,723-nucleotide RNA genome encodes 
an uninterrupted open reading frame (ORF), directing the synthesis of a polyprotein precursor in the 
order NH2-C-prM-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5-COOH, where C is the capsid protein, 
M is the membrane-associated protein, E is the envelope protein, and NS1 through NS5 are 
nonstructural proteins [5]. 
The disease has four viral serotypes (DENV 1–4), and its spectrum ranges from asymptomatic 
infection to dengue fever (DF), dengue hemorrhagic fever (DHF), and dengue shock syndrome (DSS), 
and may lead to patient death [6]. All four serotypes of dengue virus are transmitted to humans by the 
Aedes aegypti and Aedes albopictus mosquitoes [7].  
During a dengue outbreak that struck Malaysia’s Sarawak state, on Borneo, blood and serum 
samples from a severe case labeled “dengue 4” were collected, and later, the sequence of the genome 
showed that the virus occupies a new branch on the dengue family tree, suggesting the serotype 
DENV-5 [3]. Provided that this new serotype is transmissible as DENV 1–4, it might follow a similar 
pattern of geographical spread as described by Messina and co-workers. By using several maps, the 
authors demonstrated the expansion of the serotypes throughout the world, the growth of 
hyperendemicity (coexistence of multiple serotypes), and the establishment of dengue as an important 
infectious disease of global public health importance [8]. 
To date, there is no clinically approved dengue vaccine or antiviral for humans, even though there have 
been great efforts towards this end. The treatment of the disease is limited to supportive care [9,10] with 
analgesics, fluid replacement and bed rest [11]. Aspirin, non-steroidal anti-inflammatory drugs 
(NSAIDs), and corticosteroids should be avoided. Special attention should be given to severe cases of 
dengue in terms of fluid administration and treatment of hemorrhage. A placebo-controlled,   
double-blind investigation was conducted with sixty-three children having severe dengue shock 
syndrome in two hospitals in Thailand. The children were completely randomized into two groups. 
One of the groups was treated with a single dose of steroidal drug methylprednisolone and a placebo 
was administered to the other group. The study revealed that there was no significant difference in 
mortality between the groups [12].  
The cost of dengue to society is considerable, from lost wages and diminished productivity to costs 
related to care-giving and direct medical expenses. The cost of dengue in the Western Hemisphere Molecules 2014, 19  8153 
 
 
alone is estimated to be US$2.1 billion per year [13]. In view of these problems, an efficient dengue 
vaccine or antiviral is highly desirable. 
Different approaches have been used in the search for dengue antivirals, such as screening of 
compounds against dengue enzymes [14] and structure-based computational discovery [15]. During 
the last decades, researchers have turned their attention to nature, trying to identify compounds that can 
be used as dengue antivirals. In fact, nature is a fantastic reservoir of substances that can be used 
directly as pharmaceuticals or can serve as lead structures that can be optimized towards the 
development of new therapeutic agents [16–23].  
Several plants around the world present potential dengue antiviral activity. Recently, Kadir and  
co-workers reviewed sixty nine studies from 1997 to 2012 related to plants presenting potential 
antidengue activity [24]. It should be mentioned that according to a WHO factsheet, 80% of the 
population in some Asian and African countries depends on traditional medicine as their primary 
health care due to economic and geographical constraints [25–27]. In view of their few (or lack of) 
adverse effetcts, the world-wide use of medicinal plants or herbal-based medicine is steadily growing. 
Even though a number of plants are known for their antidengue activity, few investigations have 
been published related to isolation (identification) of compounds from plants and subsequent 
evaluation of their dengue antiviral activities. We describe in this review several investigations which 
resulted in the isolation (or identification) of compounds endowed with antiviral dengue activity, most 
of them isolated from plants. The review also covers metabolites isolated from other natural sources. 
2. Polysaccharides 
Fucoidans are a group of polysaccharides which contain considerable percentages of L-fucose and 
sulfate ester groups. These compounds are mainly derived from brown seaweed, and several 
bioactivities have been described for them, including antiviral ones [28–30]. Fucoidan (1, Figure 1), 
is a polysaccharide isolated from the marine alga brown seaweed Cladosiphon okamuranus. Its 
structure is composed of repeating units of sulphated fucose and glucuronic acid residues. The 
investigation conducted with Cladosiphon fucoidan (1) demonstrated that this polysaccharide 
inhibits dengue virus type 2 (DENV-2) infection [31]. The biological assays to evaluate antiviral 
activity were conducted in vitro by focus-forming assay using BHK-21 cells. Compound 1 inhibited 
virus infection in a concentration-dependent matter. When the virus was treated with 10µg/mL of 
fucoidan (1), infectivity by dengue virus serotype 2 was reduced by 80% compared with that in 
untreated cells and the determined IC50 corresponded to 4.7 µg/mL. Dengue virus serotypes 3 and 4 
were moderately susceptible to 1. For serotype 1, fucoidan (1) did not present an effect on the 
infection. Fucoidan derivatives (2–4) (Figure 1) were also examined for their effects on infection of 
BHK-21 cells by dengue virus serotype 2. Polysaccharide 2 is a derivative obtained by removal of 
the sulfated groups in fucoidan (1); derivative 3 was prepared by reduction of fucoidan (1). Fucan 
(4) is a fucose polymer.  
  Molecules 2014, 19  8154 
 
 
Figure 1. Fucoidan (1) and derivatives 2–4. 
 
The desulfation of fucoidan (1) led to derivatives 2 and 4 which showed remarkable suppression of 
inhibitory activity. This finding is in agreement with previous investigations which demonstrated that 
sulfation is required for the antiviral activity of glycosaminoglycans [32]. Even though compound 3 is 
a sulfated derivative, the reduction of carboxylic acid functionality in fucoidan (1) to the corresponding 
alcohol also resulted in a decrease of the capability of 3 in preventing serotype 2 virus infection. 
Therefore, it was concluded that the glucuronic acid residue as well as the sulphate groups are 
fundamental for the inhibitory activity of fucoidan (1) against DENV-2 [31]. It was also reported that 
glucuronic acid and sulfated fucose residues of the Cladosiphon fucoidan appear to critically affect the 
interaction of DENV-2 with cellular receptors, but the precise molecular mechanism of the inhibitory 
effects of this compound has not been elucidated. 
Several polysaccharides known as galactans have been isolated from red seaweeds [33–36]. The 
structures of these compounds correspond to a linear chain of β-D-galactopyranose residues linked by 
positions 1 and 3 (Figure 2, unit A) and residues of α-galactopyranose linked by positions 1 and 4 
(Figure 2, unit B) resulting in an arrangement in which units A and B are alternating. Natural chemical 
modifications in these structures include the presence of sulfate esters groups, pyruvate acetal and/or 
methyl ethers. In addition, unit B can exist in the 3,6-anhydro-α-galactopyranose form. 
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Figure 2. Repeating basic structure of galactans. 
 
Depending on the stereochemistry of unit B (Figure 2), the galactans can be classified as follows: (i) 
carrageenans—these correspond to sulfated polysaccharides with 4-linked α-galactose residues of the 
D-series or their 3,6-anhydro derivatives (Figure 3). Carrageenans are typically classified according to 
their structural features, including their sulfation patterns and the presence or absence of 3,6-anhydro-
α-galactopyranose on D-units. There are at least 15 different carrageenan structures, the most relevant 
being iota, kappa [Figure 3, (I)], lambda, mu, and nu [Figure 3, (II)] [37]. It is important to mention 
that natural carrageenans typically occur as mixtures of different hybrids. Moreover, methyl or pyruvic 
acid acetal moieties and the presence of small amounts of other sugars can add to the structures of 
these polysaccharides [37]. 
Figure 3. Repeating structures of carrageenans. 
 
(ii) agarans—this group of galactans differs from carrageenans in terms of the stereochemistry of 
unit B. For the agarans, the 4-linked α-galactose residues unit b correspond to the L-series. 
(iii)  DL-hybrids—these galactans are characterized by the presence of 4-linked α-galactose 
residues of the D and L series in the same molecule. Figure 4 depicts the basic repeating structure of 
DL-hybrid galactans. 
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Figure 4. Basic repeating unit of DL-hybrid galactans. 
 
Commercially available iota,  kappa and lambda carrageenans (Figure 3) were evaluated against 
DENV 1–4 serotypes [38]. The assays were conducted in vitro, using Vero and HepG2 cells and the 
activity of carrageenans was initially tested by plaque reduction assays, necessarily performed at a low 
multiplicity of infection (m.o.i.), but then confirmed by inhibition of virus yield and antigen expression 
assays, accomplished at high m.o.i. The polysaccharides were more effective on DENV-2 and DENV-3 
serotypes. It was also determined that the carrageenans lambda and iota are potent inhibitors of DENV-2 
and DENV-3 multiplication in Vero and HepG2 cells with EC50 (effective concentration 50%) ranging 
from 0.14 to 4.1 µg/mL (Table 1). The results showed that the lack of dependence of the antiviral 
potency of carrageenans on the infecting virus inoculum was even more evident when the assays were 
performed simultaneously at a wide range of multiplicities. This important property represents a clear 
advantage for those compounds able to block infection even in the presence of high initial virus doses.  
Table 1. EC50 values for inhibition of DEN-2 and DENV-3 multiplication in Vero and 
HepG2 cells. 
Polysaccharide 
EC50 (µg/mL) 
Vero Cells  HepG2 cells
DENV-2   
iota-carrageenan  0.4 ± 0.1  0.14 ± 0.01 
lambda-carrageenan  0.22 ± 0.02 0.17 ± 0.01 
DENV-3   
iota -carrageenan  1.1 ± 0.1  0.63 ± 0.01 
lambda -carrageenan 0.6 ± 0.1  0.63 ± 0.01 
This study was able to demonstrate that a heparin sulfate (HS) imitative compound lambda had the 
ability to interfere with DENV-2 replication when added after virus adsorption, and even under these 
conditions, the antiviral potential of lambda-carrageenan was higher than its ability to affect virus 
adsorption. The mechanism of the inhibitory multiplication effect of the iota carrageenan was   
not described. 
Talarico and co-workers investigated the dengue antiviral activity of two sulfated polysaccharides 
obtained from the read seaweeds Gymnogongrus griffithsiae and Cryptonemia crenulata [39]. The G3d Molecules 2014, 19  8157 
 
 
compound obtained from G. griffithsiae is a carrageenan composed of kappa/iota/nu repeating units 
(see Figure 3). The DL-galactan hybrid C2S-3 obtained from C. crenulata is made of the units 
disaccharide units (a), (b), and (c) shown in Figure 5. 
Figure 5. Disaccharides units present in the structure of C2S-3. 
 
The antiviral activity evaluation of G3d and C2S-3 was conducted in vitro and it was carried out by 
two methods: plaque reduction and virus yield inhibition assays. It was found that the dengue antiviral 
activity of sulfated G3d and C2S-3 polysaccharides depends on both virus serotype and the host cell. 
Both compounds were capable of inhibiting DENV-2 in Vero cells with IC50 values for the inhibitory 
activity close to 1 μg/mL and selectivity indexes superior to 1,000. The compounds were completely 
ineffective against DENV-1 and their inhibitory activity on DENV-3 (IC50 ranging from   
13.9–14.2 μg/mL) and DENV-4 (IC50 ranging from 29.3 to > 50 μg/mL) were significantly lower. The 
inhibitory effects of G3d and C2S-3 against DENV-2 and DENV-3 were also evaluated with respect to 
human HepG2 and foreskin PH cells as well as mosquito C6/36 HT cells. While the polysaccharides 
were totally ineffective against mosquito cells, the effectiveness of the substances with respect HepG2 
and PH cells were similar to that observed with Vero cells. From the mechanism of action standpoint, 
it was determined that G3d and C2S-3 present inhibitory effects on DENV-2 serotype only when they 
are added together with the virus or early after infection. Therefore, the processes of virus adsorption 
and internalization are the main targets of these compounds. The results suggest that these compounds 
act on virus binding. These polysaccharides may be useful tools to elucidate the mechanisms of 
binding and internalization of DENV serotypes to vertebrate and invertebrate cells, and also to 
establish structure-activity relationships [39]. 
Another study involving sulfated polysaccharides showed that the extracts and carrageenans derived 
from Meristiella gelidium were more effective inhibitors of DENV-2 compared to those derived from 
G. griffithsiae. The antiviral property evaluation was performed in vitro using Vero cells and virus 
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plaque reduction assay. In this investigation, no description on the mechanism of action for DENV 
inhibition was reported [40].  
A series of DL-galactan hybrids isolated from the red seaweed Gymnogongrus torulosus was 
assessed in vitro against DENV-2 serotype by virus reduction assay in Vero cells [41]. The repeating 
disaccharide units and the percentage of them found in the composition of the polysaccharides are 
presented in Table 2. Structures of agarose and Yaphe repeating units are shown in Figure 6.  
Table 2. DL-galactan hybrids from G. torulosus and their IC50 values when the galactans 
were evaluated against DENV-2 virus serotype. 
Polyssacharide 
MW 
(kDa) 
a 
Galactan Structure  IC50 
(μg/mL) 
c  Kappa/iota 
b  mu/nu 
b Agarose 
b Yaphe 
b 
C1 44  57  10  19  12  1.1 ± 0.2 
C2 56  1845  18  22  12  0.7 ± 0.2 
C3 77  28  21  31  14  0.34 ± 0.06 
C4 18  54  6  7  17  0.19 ± 0.03 
F1 56  76  -  19  12  0.5 ± 0.2 
F2 77  73  12  12  -  0.8 ± 0.1 
F3 18  34  -  12  51  0.9 ± 0.2 
F3T2 35  62 -  32  20  0.25 ± 0.09 
F3T4 45  38 12  40  9  0.34 ± 0.02 
F3T6 22  17 8 8  59  1.7 ± 0.1 
a Average number molecular weight. 
b Approximately percentage. 
c Inhibitory concentration required to 
reduce plaque number in Vero cells by 50%. Values are the mean of two determinations ± standard deviation 
Figure 6. Agarose and Yaphe repeating units found in DL-galactan hybrids isolated from 
the red seaweed G. torulosus. 
 
As can be seen in Table 2, the evaluated polysaccharides were very active against DENV-2 serotype 
with IC50 ranging from 0.19–1.7 μg/mL. In addition to their inhibitory activity, the compounds did not 
present cytotoxic effects on stationary or on actively dividing cells, and they presented anticoagulant 
properties. It is suggested that the mechanism of action of these compounds corresponds to 
interference in the binding of the surface glycoprotein with the cell receptor [41]. 
One aspect deserves comment at this point. Liang and co-workers prepared sulfated agarose, 
sulfated kappa-carrageenan, desulfated kappa-carrageenan, and kappa-carrageenan oligosaccharides to 
investigate their anticoagulant and cytotoxic activities. They found that anticoagulant activity and 
effects on cell proliferation are both dependent on the substitution position rather than the degree of 
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sulfate group substitution. Moreover, these activities are dependent on the secondary structures of 
polysaccharides. The investigation led to the conclusion that carrageenan and agarose can be 
considered for biomedical applications after careful tailoring of sulfate groups [42]. 
The plant storage polysaccharides known as galactomannans are characterized by a main chain of 
β-D-mannopyranosyl residues linked by positions 1 and 4 with single unit α-D-galactopyranosyl  
side-chain-residues (Figure 7). The mannose/galactose ratio depends on either the plant source or the 
extraction method used [43,44]. 
Figure 7. Basic structure of galactomannans. 
 
Ono and co-workers isolated two sulfated galactomannans [45]. One was isolated from the seeds of 
Mimosa scabrella presenting a mannose/galactose ratio of 1.1 and the other was obtained from the 
seeds of Leucaena leucocephala (mannose/galactose ratio of 1.4). These sulfated polysaccharides 
named by the authors as BRS (from M. scabrella) and LLS (from L. leucocephala) were submitted to 
in vitro and in vivo assays to assess their effects on DENV-1 (Hawaii strain) virus. The in vivo assay 
was carried out with female mice to determine antiviral activity. The in vitro evaluation was conducted 
with C6/36 cells by virus plaque reduction. Death of DENV-1-infected mice was not noticed. For the 
in vitro assay, it was found that the concentrations that produced a 100-fold decrease in virus titer were 
347 mg/L and 37 mg/L for BRS and LLS, respectively [45]. 
3. Flavonoids 
Several flavonoids have been screened for dengue antiviral activity. Figure 8 shows the structures 
of members of this class of compounds 5–9, isolated from Mexican Tephrosia species. Their antiviral 
activity was evaluated in vitro by the plaque assay using LLC-MK2 cells and DENV-2 serotype. Of the 
five flavonoids tested, only glabranine (5) and 7-O-methylglabranine (6) showed significant inhibitory 
activity (they presented 70% virus infection inhibition at 25 µmol/L). No IC50 values were reported. 
The other flavonoids 7–9 had no antiviral effect. Considering the structures of compounds 5–9, it is 
evident that a relationship exists between the structure and antiviral activity of the investigated 
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flavonoids since glabranine (5) and 7-O-methylglabranine (6), which both contain a prenyl side-chain 
at C-8, were active as replication inhibitors [46]. 
Figure 8. Structures of flanovoids from Mexican Tephrosia species 
 
The aqueous extract of Houttuynia cordata, a popular side dish vegetable consumed in Northern 
and Eastern regions of Thailand, was tested against DENV-2 [47]. The assays to evaluate antiviral 
aqueous activity were performed in vitro in three different modes: (i) protective, (ii) treatment, and (iii) 
direct blocking in HepG2 and LLC-MK2 cells. For (i) and (ii) the experiments were conducted using 
plaque titration assay, and for (iii) it was performed using plaque reduction assay. Considering HepG2 
cells, H. cordata aqueous extract displayed an inhibitory effect to DENV-2 RNA production in all 
experimental modes. The experiments were conducted at 10 μg/mL and 100 μg/mL. The higher 
concentration was effective to: (a) protect HepG2 cells from DENV-2 infection (protective mode); (b) 
decrease the intracellular viral RNA synthesis (treatment mode); (c) to inactivate the virus (direct 
blocking). The greatest inhibitory effect was observed in the protective mode. For LLC-MK2 cells, the 
experiments were conducted within 10–40 μg/mL concentration range, and the aqueous extract also 
exhibited a protective effect on virion release. High Performance Liquid Chromatography (HPLC) 
analysis identified the flavonoid hyperoside (10) as the major component of the extract (Figure 9). It is 
very likely that the observed dengue antiviral activity is associated with the presence of this flavonoid 
as the major component in the aqueous extract. The extract also protects the cells from viral entry and 
inhibits virus activities after adsorption. In the treatment mode, hyperoside (10) in the extract probably 
inhibited intracellular RNA synthesis by interacting with enzymes or proteins in the viral replication 
complex [47]. Apparently pure hyperoside-even though quite readily available from many plants- has 
not been tested as an isolated compound. 
Boesenbergia rotunda (L.) is a common spice belonging to the ginger family (Zingiberaceae). 
Figure 10 depicts the structures of the flavonoids pinostrobin (11), pinocembrin (12), alpinetin (13), 
the phenylpropanoid cardamonin (14), and the cyclohexenylchalcone derivatives pandurantin A (15) 
and 4-hydroxypanduratin A (16), all of them isolated from the aforementioned vegetal species [48].  
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Figure 9. Structure of hyperoside (10). 
 
Figure 10. Structures of compounds 11–16. 
 
These natural products were screened against DENV-2 virus NS2B-NS3 protease by enzyme assay. 
The assay was performed with the purified protease [48]. Increased concentration of the compounds 
led to increase inhibition of enzyme activity. Among the compounds, pinocembrin (12) was the least 
active inhibiting by about 60% at 400 ppm concentration. The most active substances corresponded to 
panduratin A (15) and 4-hydroxypanduratin B (16), and their inhibitory protease activities are 
presented in Table 3.  
Table 3. Percentage inhibition of DENV-2 NS2B-NS3 virus protease cleavage 
a of 
compounds 15 and 16.  
Compound 
Percentage Inhibition of DENV-2 NS2B-NS3 Protease; Concentration Used (ppm) 
40 80  120 160 240 400 
15  27.1 ± 4.8
  66.7 ± 0.1  87.7 ± 0.6  93.7 ± 0.5  92.2 ± 1.2  99.8 ± 1.1 
16  52.0 ± 1.1  78.1 ± 0.1  87.6 ± 0.4  96.0 ± 0.5  97.3 ± 0.3  99.8 ± 0.3 
a The substrate cleaved by NS3 protease used in the experiment corresponded to the peptide Boc-Gly-Arg-
Arg-MCA. ± corresponds to standard deviation. 
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Interestingly, although the compounds 12 and 14 had low inhibitory activity on NS2B-NS3 
protease, some synergistic effect was noticed when these compounds were mixed (Table 4). 
Table 4. Percentage inhibition of DENV-2 NS2B-NS3 virus protease cleavage 
a of 
compounds and 12 and 14.  
Compound 
Percentage Inhibition of DENV-2 NS2B-NS3 Protease; 
Concentration Used (ppm) 
120 240  400 
12  30.1 ± 0.5
  47.3 ± 0.5  56.1 ± 0.4 
14  39.4 ± 0.6  50.1 ± 0.4  71.3 ± 0.3 
12 + 14  52.6 ±0.4  63.5 ± 0.5  81.8 ± 0.3 
a The substrate cleaved by NS2B-NS3 protease protease used in the experiment corresponded to the peptide 
Boc-Gly-Arg-Arg-MCA. ± corresponds to standard deviation. 
For the most active compounds 15 and 16, it was determined that they present competitive inhibitory 
activity on NS2B-NS3 displaying inhibitory constants (Ki) of 21 and 25 μmol/L, respectively. 
The flavonoids quercetin (17), naringenin (18) daidzein (19), and hesperetin (20) (Figure 11) were 
evaluated against DENV-2 serotype by Zandi and co-workers. The assessment of antiviral activity was 
conducted in vitro utilizing Vero cells. DENV replication was measured by Foci Forming Unit Reduction 
Assay (FFURA) and quantitative real time polymerase chain amplification (qRT-PCR). [49]. Of these 
compounds, only quercetin (17) presented significant inhibitory activity (IC50 was 35.7 μg/mL) against 
DENV-2 infection in Vero cells. The selective index for quercetin when the infected cells were treated or 
when uninfected cells were treated continuously 5h before infection until 4 days post infection were 7.07 
and 8.74, respectively. The mechanism by which quercetin exerts its antiviral effect remains unknown. 
However, it is believed that DENV antiviral activity of 17 could be similar to that presented by others 
flavonoids that act against cellular RNA polymerases and formation of the complex with RNA [49]. 
Figure 11. Structures of compounds 17–20. 
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The study of Zandi and co-workers evaluated the effects of naringenin (18) (Figure 11), rutin (21), 
and fisetin (22) (Figure 12) against DENV-2 (NGC strain). Antiviral effects of each compound at the 
different stages of DENV-2 infection were examined in vitro using FFURA and qRT-PCR. The 
authors found that among the flavonoids studied only 22 presented significant in vitro activity on 
dengue virus replication activity [50]. Compound 22 did inhibit virus replication (IC50 of 55 µg/mL 
and selectivity index of 4.49) after virus adsorption on Vero cells. When Vero cells were continuously 
treated for 5 h before virus infection and continuously up to 4 days post-infection, IC50 corresponded to 
43.12 µg/mL and selective index of 5.72. The authors report that no virucidal or prophylactic activity 
was noticed for fisetin (22). Even though compounds 18 and 21 did not inhibit DENV-2 replication, 
flavonoid 18 displayed virucidal activity (IC50 of 52.64 µg/mL), albeit with a low selectivity index (<1). 
The mechanism of how fisetin affects DENV virus replication is unclear. For the authors, it is not 
likely to act directly on the virus, because it does not affect DENV-2 binding to cells. They believe that 
fisetin (22) could affect DENV genome copy number by interference in DENV-2 replication (by 
binding directly to virus RNA or forming a flavonoid-RNA complex) or by affecting the RNA 
polymerases resulting in inhibition of virus replication [50]. 
Figure 12. Structures of rutin (21) and fisetin (22). 
 
A biological screening conducted on 1,350 ethyl acetate extracts prepared from various parts of 
approximately 650 New Caledonian plants was carried out targeting the DENV-2 NS5 polymerase. 
Enzyme assays were performed. DENV-2 NS5 polymerase genes were tagged by six N-terminal 
histidine residues and expressed from the pQE30 vector (Qiagen, Venlo, Limburg, Netherlands) in   
E. coli Rosetta pLacI cells (Novagen,  Darmstadt, Germany). The enzymes were produced and purified 
by Heparin-Sepharose Chromatography. Alternatively, gel filtration was used as a second purification step. 
Polymerase activity was assayed by monitoring the incorporation of radiolabeled guanosine into a 
homopolymeric cytosine RNA template. Among several active extracts, the very active one from the 
bark of Cryptocarya chartacea Kostern, a species belonging to the Lauraceae family [51] was selected. 
From the selected extract, it was isolated the non-alkylated flavonoid pinocembrin (12) as well as 
series of new mono and dialkylated ones named chartaceones A-F (23–32, Figure 13). The screening of 
compounds  23–32 against DENV-2 NS5 polymerase showed that the chartaceones C-F (compounds   
29–32) were the most active in inhibiting polymerase activity (IC50 ranging from 1.8 to 4.2 µmol/L) while 
the other chartaceones were less effective. On the contrary, compound 12 was completely inactive. 
These findings suggest that the presence of alkylated chains in the structures of chartaceones C-F  
(29–32) play important role in terms of inhibitory activity on DENV-2 NS5 polymerase. The 
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compounds 12, 23–33 were also screened against bovine diarrhea virus (BVDV) NS5 polymerase and 
no activity was observed. Therefore, it seems that these natural substances present some selectivity 
towards DENV2-NS5 polymerase. Considering that the activity of compounds 29–32 against DENV-2 
NS5 polymerase was similar, it was concluded that side chains A and B (Figure 13) play an equivalent 
role in terms of biological activity [51]. Figure 14 shows the structures of the last two compounds 
discussed in this section. 
Figure 13. Structures of pinocembrin and chartaceones. 
 
Figure 14. Structures of compounds 33–35. 
 
Scutellaria baicalensis is a tradicional Chinese medicinal herb belonging to the Lamiaceae family. 
From the roots of this species, baicalein (33) is usually extracted [52]. The authors conducted in vitro 
assay using Vero cells an FFURA to assess antiviral activity against DENV-2. This flavonoid inhibited 
DENV-2 serotype replication in Vero cells displaying an IC50 of 6.46 µg/mL and a selectivity index of 
17.8 when it  was added after adsorption to the cells. The IC50 against DENV-2 is 5.39 µg/mL   
and the selectivity index increased to 21.3 when Vero cells were treated before virus infection and 
continuously up to 4 days post-infection. Substance 33 displayed direct virucidal (IC50 of   
1.55 µg/mL) as well as anti-adsorption (IC50 of 7.14 µg/mL) effects against DENV-2. The results 
suggest that a possible mechanism for the extracellular and intracellular activities of baicalein (33) 
against DENV-2 could be attributed to its ability to bind and/or to inactivate important structural 
and/or non-structural protein(s) of DENV-2 [52]. 
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A phytochemical investigation of the ethanol extracts from Distictella elongate (Vahl) Urb led to 
isolation of petcolinarin (34) from the leaf extract and a mixture of 34 and acacetin-7-O-rutinoside (35) 
from fruit extract. In vitro MTT colorimetric assays, using Vero and LLCMK2 cells, were conducted 
to assess antiviral activity against DENV-2. The mixture of 34 and 35 presented better anti-DENV-2 
activity (EC50 of 11.1 ± 1.6 µg/mL and selectivity index > 45) than pure petcolinarin (34) (EC50 of  
86.4 ± 3.8 µg/mL and selectivity index of 4.6). The mechanism of inhibition of the compounds is 
unclear, but it is suggested that it may correspond to one of the putative mechanisms already described 
for flavonoids [53]. 
4. Alkaloids and Related Compounds 
Emetine (36, Figure 15) is a compound belonging to the ipecacuanha alkaloids. Its dihydrochloride 
was identified by Low and co-workers as a compound displaying potent DENV antiviral activity at a 
very low concentration of 0.5 µmol/L (277 ng/mL) [54]. The investigators conducted in vitro 
experiments using Huh-7 and BHK21 cells via viral plaque assay associated with immunofluorescence 
assay and qRT-PCR. A series of experiments led to the conclusion that emetine dihydrochloride acts 
inhibiting DENV infection at the early stages of viral replication life cycle, either affecting the viral 
RNA synthesis pathway or viral protein translation pathway. 
Figure 15. Structures of alkaloids 36–38. 
 
Coptis chinensis Franch is a medicinal plant used in China to treat bacterial, inflammatory, fungal 
and other diseases, presenting no significant side effects or toxicity to humans at clinical doses [55]. 
This vegetal species presents a high concentration of palmatine (37, Figure 15) which was screened  
in vitro for its antivirus activity against DENV-2 using Vero cells via viral titer reduction assays. Vero 
cells were infected with DENV-2 and the EC50 was estimated to be 26.4 µmol/L and the selectivity 
index to be 39. In the same work, the authors demonstrated in an enzyme assay that palmatine (37) 
could inhibit the NS2B-NS3 protease of West Nile Virus (WNV). The mechanism by which alkaloid 
37 inhibits the virus is not clear yet; the authors of this investigation plan to clarify the mechanism of 
action mainly based on a viral reverse genetics system, virus-encoded proteases and selection and 
characterization of palmatine-resistant viruses [55]. 
The water soluble castanospermine (38), Figure 15, is derived from Castanospermum australe 
(black bean or Moreton Bay chestnut tree). An in vitro and in vivo experiments were conducted to 
ascertain whether this alkaloid can inhibit all dengue virus serotypes. The in vitro experiment used to 
investigate antiviral activity used BHK-21 cells in a plaque reduction assay and was verified with 
western blotting, ELISA and fluorogenic RT-PCR. In vivo experiment was also conducted with A/J 
mice (28 to 31 days old). Alkaloid 38 inhibits all dengue virus serotype infections in vitro and dengue 
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virus serotype 2 in vivo. It was found that inhibition occurs at the level of secretion and infectivity of 
viral particles. Additionally, castanospermine (38) prevented mortality in a mouse model of dengue 
virus infection, with doses of 10, 50, and 250 mg/kg of body weight per day being highly effective at 
promoting survival [56]. 
The aminoglycoside geneticin (39, Figure 16) presents antiviral activity against bovine viral diarrhea 
virus (BVDV). Taking into consideration that dengue virus, yellow fever virus and BVDV are in the 
Flaviviradae family, Zhang and co-workers undertook the task of screening 39 against dengue virus.  
Figure 16. Structure of the aminoglycoside geneticin (39). 
 
The antiviral activity was assessed in vitro with BHK cells by viral plaque reduction assay with 
western blotting and qRT-PCR. The results demonstrated that compound 39 inhibits DENV-2 
proliferation by: (i) protecting BHK cells against the cytopathic effect of DENV-2 (EC50 of   
3 ± 0.1 µg/mL for this activity); (ii) reducing the viral yield (EC50 of 2 ± 0.1 µg/mL and EC90 of  
20 ± 2 µg/mL); (iii) inhibiting DENV-2 plaque formation in both the number and the size of the 
plaques (EC90 of 25 µg/mL); (iv) blocking DENV-2 RNA and protein synthesis. It was also found that 
the selectivity index of 40 was equal to 66 [57]. While compound 40 was active against DENV-2, no 
inhibition was observed on yellow fever virus in the screening with BHK cells. The molecular 
mechanism of antiviral activity of geneticin (40) remains unclear. The results suggest that the 
geneticin-mediated antiviral mechanism is cell type-independent [57]. 
5. Terpenoids 
The bark and the wood of Trigonostemon cherrieri, a rare plant of New Caledonia, were 
investigated for their chemical composition resulting in the isolation and characterization of several 
oxygenated terpenes , among them compounds 40–42 (Figure 17). 
The compounds were evaluated for the ability to interfere with NS5 DENV polymerase by an 
enzyme assay with purified enzyme. All of them indeed presented inhibitory effects on enzyme activity 
with the IC50 of 12.7 ± 0.2, 3.1 ± 0.2 and 16.0 ± 1.3 µmol/L for compounds 40, 41, and 42, respectively. 
There is no report on the mechanism of inhibition of the compounds [58]. 
  
O
HO
H3C
NHCH3
OH
O
NH2
HO NH2
O O
CH3
OH
H
OH
OH
H2N
(39)Molecules 2014, 19  8167 
 
 
Figure 17. Structures of terpenes 40, 41 and 42. 
 
A bioguided investigation aimed to obtain antiviral chemical constituents from an ethanol extract of 
leaves from Arrabidaea pulchra resulted in the isolation of triterpene compound 43 along with 
phenolic derivatives 44 and 45 (Figure 18). 
Figure 18. Structure of terpenoid 43 and phenolic compounds 44 and 45. 
 
The isolated compounds displayed activity against DENV-2. Cytotoxity was determined in vitro 
against LLCMK2 and Vero cells by MTT colorimetric assay. The determined EC50 and the selectivity 
indexes for the compounds were as follows: 43 (EC50 = 3.2 ± 0.6 µg/mL; selectivity index = 3.1); 44  
(EC50 = 2.8 ± 0.4 µg/mL; selectivity index = 20.0); 45 (EC50 = 3.4 ± 0.4 µg/mL; selectivity index = 3.8). 
The same assay was conducted with Human Herpesvirus-1 (HSV-1), Vaccinia Virus Western Reserve 
(VACV-WR) and Murine Encephalomyocarditis virus (EMCV). The inhibition of HSV-1 and   
VACV-WR was lower than that of DENV-2, and no inhibition was observed for EMCV. Further 
investigations are needed to understand the mechanisms of the antiviral activity, especially for 
compound  45 which displayed the lowest toxicity in LLCMK2 cells and was active only against 
DENV-2. Further assays are also needed to investigate virucidal activity and targets in the viral 
replication cycle [59]. 
6. Polycyclic Quinones 
The marine environment has been explored in the interests of identification of new leads for 
pharmaceutical purposes including antivirals [60]. The polycyclic gymnochrome D (46) and 
isogymnochrome D (47) (Figure 19) were isolated from the living fossil crinoids Gymnocrinus richeri [61]. 
The assessment of their effect on DENV-1 (strain Hawai/1944) virus was conducted in vitro using 
porcine PS cells in a plaque reduction assay. The results showed that they display antiviral activity. 
This activity was determined by the reduction of foci (RF) formed by DENV-1 compared with 
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controls. Thus, for compound 46 and 47, the determined RF50 was smaller than 1 µg/mL. The 
mechanism by which the compounds could inhibit the virus was not reported [61]. 
Figure 19. Structures of polycyclic quinones 46 and 47. 
 
The polycyclic quinones hypericin (48), tetrabromohypericin (49) and gymnochrome B (50)  
(Figure 20) were also examined for both their antidengue virus activities and their photoactivities. In this 
investigation researchers conducted an in vitro experiment with PS cells by plaque reduction assay against 
dengue virus serotypes 2 and 4. It was determined that all of these quinones presented virucidal an antiviral 
activities which are enhanced by light. The virucidal activity presented the following increasing order of 
potency: tetrabromohypericin (49) (ED50 = 2.8 nmol/mL); hypericin (48) (ED50 = 1.8 nmol/mL); 
gymnochrome B (50) (ED50 = 0.042 nmol/mL). A similar trend was found for the antiviral effect: 
tetrabromohypericin (49) (ED50 = 3.7 nmol/L); hypericin (48) (ED50 = 0.6 nmol/mL); gymnochrome B 
(50) (ED50 = 0.029 nmol/L). ED stands for effective dose. The tested doses ranged from 50 to   
0.001 µg/mL. Considering that the most active compound was gymnochrome B (50), it is apparent that the 
presence of the side chain in the structure of compound 50 seems to be beneficial for both virucidal and 
antiviral activities. [62].  
Figure 20. Structures of polycyclic quinones 48, 49 and 50. 
 
7. Phenolics 
The screening of 850 ethyl acetate extracts of Madagascan plants was carried out resulting in the 
isolation of several phenolic glycosides from Flacourtia ramontchi. To assess antiviral activity, the 
authors conducted enzyme assays with purified enzyme NS5 polymerase of dengue virus.  The 
substances 51 and 52 (Figure 21) were the most active phenolic derivatives evaluated against DENV 
NS5 polymerase. The observed activity was moderate and the determined IC50 values were   
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9.3 ± 2.8 μmol/L for 51 and 9.5 ± 5.0 μmol/L for 52. The mechanism of action of these compounds 
needs to be further investigated [63]. 
Figure 21. Phenolic glycosides 51 and 52. 
 
Rahman and collaborators conducted an in vitro experiment with C6/36 cells by MMT colorimetric 
assay against Dengue Virus serotype 2, and an enzyme assay with purified DENV-2 NS2B/3. Methyl 
gallate (53, Figure 22) which was purified from the methanol extract of Quercus lusitanica inhibited 
98% of DENV-2 NS2B/3 protease at 0.3 mg/mL. Infected and treated C6/36 cells showed that the 
treatment with crude methanol extracts as well as methyl gallate (53) purified from the extract   
down-regulated the expression of the NS1 protein. This result could be related to a reduction or 
absence of a cytopathic effect on infected C6/36 cells [64].  
Figure 22. Structure of methyl gallate (53). 
 
8. Miscellaneous 
Several other compounds (Figure 23) have been reported to possess antivirus activity. Zoasteric 
acid (54) is obtained from the temperate marine eelgrass, Zastera marina. Rees and collaborators 
conducted in vitro experiments with LLCMK-2 cells by focus forming unit reduction assay and   
qRT-PCR to evaluate if compound 54 could inhibit all serotypes of dengue virus. Compound 54 
presented a modest antiviral activity against serotype 2 with IC50 of approximately 2.3 mmol/L .This 
investigation also identified the synthetic analogue of zoasteric acid (55) as a more active compound 
concerning antidengue activity. It presented inhibitory effects against all DENV serotypes displaying 
IC50 of 24, 46, 14 and 47 μmol/L against DENV-1, DENV-2, DENV-3 and DENV-4, respectively. The 
analogue  55 showed support of inhibition at an entry step in the viral life cycle and enhanced   
virus-cell binding as evidenced by a quantitative RT-PCR assay system. The idea that compound 55 
interferes  with entry by promoting inappropriate virus-cell contacts would lend support to the 
hypothesis that these compounds function through binding to attachment domains on adherent 
organisms and subsequent release from the protected surface [65]. 
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Squalamine (56) was first discovered in the tissues of the dog fish shark (Squalus acanthias) and 
later identified within the circulating white blood cells of the sea lamprey (Petromyzon marinus). The 
in vitro effect of squalamine (56) on dengue virus infection of human endothelial cells (HMEC-1) was 
evaluated by the plaque assay. At the concentration of 40 µg/mL, dengue infection was inhibited by 
60%. The infection was completely suppressed at 100 µg/mL. The proposed mechanism of action 
involves the capacity of squalamine (56) to neutralize the negative electrostatic surface charge of 
intracellular membranes in a way that renders the cell less effective in supporting viral replication [66]. 
Figure 23. Structures of compounds 54–62. 
 
Table 5. Bioactivities determined for glycyrrhizin (58) against DENV-1-3. 
Virus Serotype  EC50 
a (μg/mL) EC90 
b (μg/mL) 
Selectivity Index 
c 
Based on CC50  
of Confluent Cells 
d 
Based on CC50 for  
Growing Cells 
e 
DENV-1 450.0  316  >6  6 
DENV-2 174.2  317  >6  5 
DENV-4 632.7  416  >6  4 
a Effective concentration required to reduce virus-induced cytopathogenicity by 50%; 
b Effective 
concentration required for inhibition of virus yield; 
c Seletivity index (CC50 divide by EC50); 
d Calculated 
from confluent cells, CC50 > 3000 μg/mL; 
e Calculated from exponentially growing cells, CC50 = 2500 μg/mL. 
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Crance and co-workers evaluated glycyrrhizin (57), the major component responsible for the   
sweet-tasting constituent of Glycyrrhiza glabra (liquorice) root, against eleven flaviviruses including 
DENV-1, DENV-2, and DENV-3 [67]. The antiviral evaluation was performed in vitro with Vero cells 
by plaque reduction assay. Several bioactivities were determined for this compound and they are 
summarized in Table 5. This antiviral compound has already been used in patients in the treatment of 
other diseases. It should be further considered for use, either alone or in combination with another 
antiviral compounds tested in this work (interferon, ribavirin, 6-azauridine) for the treatment of 
flavivirus infections. 
Narasin (58) is a polyether antibiotic and antibacterial produced by fermentation of Streptomyces 
aureofaciens. A dose-dependent study revealed that 58 has a 50% inhibitory concentration of less than 
1  μmol/L against all four DENV serotypes [68]. Minimal cytotoxicity was determined for this 
compound (50% cytotoxic concentration > 1,000 μmol/L). In vitro assays with Huh-7 cells by plaque 
assay with different concentrations, qRT-PCR, western blotting and ultrastructural imaging were 
performed in this investigation. Narasin (58) treatment of DENV-2 infected Huh-7 cells suggested that 
the compound is involved in inhibiting the post-entry stages of viral replication during DENV 
infection. The antiviral mechanism of narasin (58) is likely to be associated with the disruption of viral 
protein synthesis. No differences of RNA levels were found between narasin (58) treated and DENV-2 
infected cells. The study indicated a characteristic disruption of viral protein synthesis by substance 
(58) without affecting viral RNA replication. However, a more detailed investigation is required to 
understand the exact molecular mechanism of narasin (58) in the inhibition of DENV protein synthesis 
and replication [68]. 
The acetylenic compounds 59–62 were isolated from an ethyl acetate extract of Anacolosa 
pervilleana, a Madagascan plant. By using purified DENV RdRp polymerase in enzyme assay, it was 
found that acetylenic compounds 59–62 give rise to IC50 values around 3 μmol/L in the DENV RdRp 
assay. The results show that compounds possess some selectivity toward DENV RdRp. All compounds 
except 59 showed an overall antimetabolic effect in Vero cells (CC50s between 20 and 30 μmol/L). 
The presence of an additional acidic group in compound 59, probably prevents its penetration through 
the cell membrane, which may explain the absence of cytotoxicity [69]. 
9. Conclusions  
During the last decades, the exploitation of the natural product pool has afforded a variety of 
compounds possessing activity against dengue virus serotypes. In several cases, very interesting 
activities are associated with the described compounds. It can be stated, though, that only a small 
fraction of the vast reservoir of compounds available from nature has been explored with the aim to 
find antivirus effective against dengue. From nature, it is possible that effective dengue antiviral 
compounds with low toxicity to human beings will certainly be found. Moreover, the structures of the 
natural compounds can serve as prototypes that can be optimized by synthetic campaigns in order to 
find even more active substances against dengue virus. 
Most of the studies herein described were conducted in vitro using different plaque assays, 
including the focus forming assay, plaque reduction assay, plaque titration assay, virus yield reduction 
assay and MMT colorimetric assay. Some of these studies [38,39,47,49,50,54,56,57,64,65,68] sought Molecules 2014, 19  8172 
 
 
to use more than one methodology to perform and/or verify the antiviral activity, giving greater 
strength to the results. Only three authors conducted in vivo studies [45,56], using animals, which 
further demonstrates the urgent need to make progress in these experiments to find a useful and 
effective antiviral against dengue. All of them were associated with in vitro assays. Seven enzyme 
assays, four against DENV NS5 polymerase [51,58,63,69] and three against DENV NS2B/NS3   
protease [48,55,64] were conducted. The tests used are well established and are ideal for this type of 
research. It is also necessary to carry out more extensive studies both in vitro and in vivo followed by 
toxicity and clinical tests to further evaluate the potential of compounds obtained from nature as 
dengue antivirals. Finally, subsequent in vivo testing will indicate which of these substances are going 
to be the most promising in antiviral therapies against dengue, since efficiency in vitro does not 
necessarily have a parallel in vivo. 
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